This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Wallace W. Tourtellotte, MD, PhD; Karl Syndulko, PhD; Alfred R. Potvin, PhD
Neurology Service Veterans Administration Wadsworth Medical Center Wilshire and Sawtelle boulevards Los Angeles, CA 90073

Arch Neurol. 1981;38(11):737-738.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

This letter is in reply to the letter by Weiner and Nausieda (ARCHIVES 1981;38:534) concerning our article published in the ARCHIVES (1980;37:723-726). Drs Weiner and Nausieda stated that our "study of the use of an increased ratio of carbidopa to levodopa in the treatment of Parkinson's disease is rather difficult to interpret." They also raised some specific questions regarding the study and some general issues regarding the treatment of Parkinson's disease. We will address these in the order they were presented in their letter.

Weiner and Nausieda stated, "The response of the patients to these three different treatment regimens after a two-week period was used to conclude that increasing the amount of carbidopa in presently available drugs is a desirable treatment modality." In fact, we concluded that "increasing the amount of carbidopa from 10 to 20 mg per 100-mg dose of levodopa gives a greater therapeutic response . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?